A combination of enfortumab vedotin and pembrolizumab has shown promising results in treating patients with advanced bladder cancer, nearly doubling survival rates compared to chemotherapy. Additionally, Johnson & Johnson’s TAR-200 represents a novel treatment prospect, designed to sustain the local release of chemotherapy drug gemcitabine directly into the bladder. Breakthrough nanotechnology in the form of urea-powered nanorobots has also shown great potential, achieving a 90% reduction in bladder tumor size in a mouse model. These advances indicate a promising future for more targeted, effective, and less invasive bladder cancer treatments.
Vshell Gains Traction Among Threat Actors as an Alternative to Cobalt Strike
A Go-based command-and-control (C2) framework originally marketed within Chinese-speaking offensive security communities has been quietly expanding its reach, drawing growing attention from threat actors seeking
